CTLA4 and metastatic melanoma: Immune checkpoint inhibitors (ICIs) such as nivolumab (a programmed cell death protein 1 {PD-1} inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated protein 4 {CTLA-4} inhibitor) have significantly improved outcomes in various malignancies, including metastatic melanoma.